Table 2 Cox regression models for overall survival in all patients, in all NSCLC patients and in stage IV NSCLC patients,

From: Soluble Triggering Receptor Expressed on Myeloid Cells 1 in lung cancer

study population (n = 164)

HRb

FWDa

95% CIc

pd

Agee

  

0.235

Sexf

  

0.987

Histologyg

  

0.099

Metastasish

  

3.9 × 10−11

sTREM-1i

1.48

1.06–2.06

0.020

Subpopulation A (n = 137)

HR b

FWD a

95% CI c

p d

Agee

  

0.058

Sexf

  

0.816

sTREM-1i

1.6

1.08–2.39

0.011

Stage

  

4.9 × 10−11

  1 vs. 2

1.8

0.61–5.17

 

  2 vs. 3

3.0

1.38–6.64

 

  3 vs. 4

8.3

3.81–18.01

 

Histology

  ACj

  

0.163

  SCCk

  

0.388

  LCCl

  

0.081

Subpopulation D (n = 75)

HR b

FWD a

95% CI c

p d

Agee

  

0.518

Sexf

  

0.175

sTREM-1i

1.94

1.17–3.2

0.008

Histology

  ACj

  

0.193

  SCCk

  

0.706

  LCCl

  

0.137

  1. aForward likelihood ratio model,
  2. bHazard ratio: HR < 1 suggests improved survival,
  3. cConfidence interval,
  4. dP-value according to the likelihood ratio test,
  5. ePer anno,
  6. fFemale vs. male,
  7. gNSCLC vs. SCLC,
  8. hM0 vs M1,
  9. iSTREM-1 lower vs. higher than 163.1 pg/ml,
  10. jO ther NSCLC vs. adenocarcinoma,
  11. kOther NSCLC vs. squamous cell carcinoma,
  12. lOther NSCLC vs. large cell carcinoma.